365mc Partners with Raziel Therapeutics to Advance RZL-012 Injectable Fat Reduction Treatment in South Korea
Key Insights
365mc (search), South Korea's leading fat reduction medical institution, has formed a strategic collaboration with Raziel Therapeutics (search) to jointly develop RZL-012, an injectable treatment for focal fat reduction currently progressing toward Phase 3 trials.
RZL-012 is a novel chemical entity designed to selectively disrupt adipocyte (search) membranes, inducing cell death and resulting in significant and lasting reduction in fat volume at injection sites for aesthetic applications.
The partnership will combine RZL-012 with 365mc (search)'s proprietary LAMS surgical technique to develop next-generation body contouring protocols, with 365mc making a strategic investment in Raziel Therapeutics (search).
365mc (search), South Korea's leading medical institution specializing in fat reduction treatments, has announced a strategic collaboration with Raziel Therapeutics (search) to jointly advance the clinical and commercial development of RZL-012 in South Korea. The partnership focuses on RZL-012, an innovative injectable treatment for focal fat reduction that is currently progressing toward Phase 3 trials.
Novel Mechanism of Action
RZL-012 represents a novel chemical entity (NCE) designed to selectively disrupt adipocyte (search) membranes, leading to a reduction in localized subcutaneous fat. Clinical trials have demonstrated that RZL-012 induces adipocyte cell death, resulting in a significant and lasting reduction in fat volume at the injection site. The drug is intended for aesthetic applications, including the treatment of submental fat (search) ("double chin") and non-surgical body contouring.
Strategic Partnership Framework
Through this collaboration, the two companies will jointly design and implement the Phase 3 clinical strategy for RZL-012 in South Korea. 365mc (search) will leverage its extensive clinical experience, regulatory expertise, brand-building capabilities, and market access to play a critical role in positioning RZL-012 as a best-in-class solution in the Korean aesthetic medicine market.
365mc (search) operates as South Korea's No.1 medical network specializing in fat management and reduction, with 21 branches nationwide. The organization is renowned for its patient-centered and comprehensive approach to fat management, offering an integrated continuum of services encompassing surgical procedures, dietary counseling, and behavioral therapy.
Combination Therapy Development
The companies will explore the development of a next-generation body contouring protocol by combining RZL-012 with 365mc (search)'s proprietary LAMS (Liposuction Assisted Modeling System) procedure. LAMS is an innovative surgical technique for focal fat reduction developed by 365mc and is expected to serve as a platform for global market expansion through an integrated treatment solution.
Investment and Global Expansion
As part of this partnership, 365mc (search) will make a strategic investment in Raziel Therapeutics (search), further underscoring its commitment to advancing innovation in the field of non-surgical fat reduction. The agreement was initiated and facilitated by Yozma Group (search), a Nasdaq-focused strategic investment firm that has been supporting Raziel Therapeutics' global expansion.
365mc (search) is rapidly expanding its global presence, with successful market entries in Indonesia, Thailand, and Vietnam, and a recent expansion confirmed in the United States, positioning the company as a leading international authority in body contouring.
Market Impact
This partnership represents a convergence of 365mc (search)'s leadership in obesity (search) and aesthetic medicine with Raziel Therapeutics (search)' cutting-edge fat reduction technology. Together, the companies are poised to set a new global standard in non-invasive body contouring, not only in South Korea but across international markets.